首页 | 本学科首页   官方微博 | 高级检索  
     


Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C
Authors:Maria Buti,Kosh Agarwal,Yves Horsmans,William Sievert,Ewa Janczewska,Stefan Zeuzem,Lisa Nyberg,Robert S. Brown Jr.,Christophe Hé  zode,Mario Rizzetto,Raymundo Paraná  ,Sandra De Meyer,Ralph De Masi,Donghan Luo,Kirk Bertelsen,James Witek
Affiliation:1 Liver Unit, Department of Internal Medicine, Hospital Valle Hebron and Ciberehd del Institut Carlos III, Barcelona, Spain;2 Institute of Liver Studies, Kings College Hospital, London, England;3 Clinical Pharmacology Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium;4 Gastroenterology and Hepatology Unit, Monash Medical Centre and Monash University, Melbourne, Australia;5 Outpatients Clinic for Hepatology, Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland;6 Department of Medicine I, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany;7 Hepatology Research Department, Kaiser Permanente, San Diego, California;8 Department of Hepatology and Gastroenterology, Columbia University College of Physicians and Surgeons, New York, New York;9 Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Créteil, France;10 Department of Hepatology and Gastroenterology, University of Torino, Torino, Italy;11 Gastro-Hepatology Unit, Medical School, Federal University of Bahia, Bahia, Brazil;12 Janssen Infectious Diseases BVBA, Beerse, Belgium;13 Janssen Research & Development LLC, Titusville, New Jersey
Abstract:
Keywords:OPTIMIZE   Clinical Trial   Protease Inhibitor   DAA
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号